Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 7/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18440370 | 0.86 | TNK2 (0.39) | BTKDPP4CYP2D6DPP8DPP9 | |
| SCHEMBL1190088 | 0.86 | PRMT5 (0.41) | TRPV1 | |
| SCHEMBL27987045 | 0.83 | TNK2 (0.38) | BTKCSF1RHCRTR1HCRTR2GRM5 | |
| SCHEMBL28814728 | 0.83 | TNK2 (0.38) | BTKCSF1RHCRTR1HCRTR2GRM5 | |
| SCHEMBL27987039 | 0.83 | TNK2 (0.38) | BTKCSF1RHCRTR1HCRTR2GRM5 | |
| SCHEMBL15056902 | 0.72 | STK17B (0.51) | TRPV1KMT2A | |
| SCHEMBL16336962 | 0.72 | STK17B (0.51) | TRPV1KMT2A | |
| SCHEMBL16337923 | 0.72 | STK17B (0.51) | TRPV1KMT2A | |
| SCHEMBL15056838 | 0.72 | PRMT5 (0.43) | TRPV1 | |
| SCHEMBL15056219 | 0.72 | PRMT5 (0.43) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | BTK 2950/4885DPP4 67/4885CYP2D6 1998/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | BTK 2400/4885DPP4 180/4885CYP2D6 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.